The Next GLP-1 Moment? Why Big Pharma Is Investing in Depression

Only a few years ago, psychedelic medicine sat on the fringes of pharmaceutical research. Today, it has become one of the industry’s fastest-growing investment areas.

In July, Eli Lilly announced a $2.8 billion acquisition of Atai Beckley, gaining access to BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression. It wasn’t an isolated move. Johnson & Johnson has already demonstrated that rapid-acting therapies for depression can become commercially successful with Spravato, the first blockbuster in this category. Otsuka, already a global leader in psychiatry with medicines such as Abilify and Rexulti, continues to expand its neuroscience portfolio, while other large pharmaceutical companies are actively evaluating opportunities in next-generation treatments for depression.

At first glance, this looks like a story about psychedelics. In reality, it’s about one of medicine’s biggest unmet needs: depression. More specifically, it’s about one of the largest unmet needs in medicine finally attracting the level of investment usually reserved for oncology or obesity.

Depression has become impossible to ignore

More than 280 million people worldwide live with depression. While many patients benefit from existing antidepressants, millions with treatment-resistant depression continue to cycle through multiple therapies without meaningful improvement.

That makes depression one of the largest unmet needs in medicine and one of pharma’s biggest commercial opportunities.

The comparison with obesity is hard to ignore. A decade ago, obesity was seen as a difficult market with limited potential. Then GLP-1 therapies transformed it into one of the industry’s biggest growth stories.

Depression may now be approaching a similar turning point. Investment is accelerating, scientific innovation is gaining momentum, and Big Pharma is positioning itself early. The next breakthrough may not simply come from a better molecule, but from the companies that can successfully bring these therapies through late-stage clinical development.

Why now?

Three things have changed.

• First, commercial proof already exists.

Johnson & Johnson showed that rapid-acting therapies for treatment-resistant depression can succeed commercially. Just as importantly, Spravato helped establish specialized treatment centers, trained investigators and clinical infrastructure that future therapies can build upon.

• Second, the science has matured.

The field no longer depends on a single company or a single molecule. Multiple developers are advancing different approaches, including DMT, psilocybin and LSD derivatives. Every successful study reduces uncertainty for the next one, gradually increasing confidence among regulators, physicians and investors.

• Third, investor confidence has shifted.

The conversation is no longer whether psychedelic therapies have a future. The question is which companies will define this new therapeutic category.

Money doesn’t guarantee success

Large acquisitions often create the impression that the hardest part is over. In reality, they usually mark the beginning of the most difficult stage. Neuroscience remains one of the highest-risk areas of drug development. Promising early data frequently fail to translate into regulatory approval, and psychedelic therapies bring additional scientific and operational challenges.

The FDA’s Complete Response Letter to Lykos Therapeutics’ MDMA-assisted therapy in 2024 was a reminder that excitement around a new therapeutic approach does not replace robust clinical evidence.

Clinical development will decide the winners

Clinical development will determine what happens next. Unlike many other therapeutic areas, psychedelic therapies introduce challenges that traditional trial designs were never built to solve.

• Maintaining blinding is far more difficult, as patients can often recognize whether they received the active treatment.
• Measuring efficacy is more complex, with clinical benefit relying on psychiatric rating scales and patient-reported outcomes rather than objective biomarkers.
• Standardizing treatment across sites is uniquely challenging, as many investigational programs combine the drug with structured psychological support, requiring consistent delivery across investigators, sites and countries.

Success will depend on far more than a promising molecule. Patient selection, endpoint strategy, investigator training, site experience and consistent execution across global studies may ultimately determine which therapies reach regulatory approval.

 What this means for sponsors

Entering this field means preparing for a very different type of clinical program.

Success will depend on experienced sites, well-trained investigators, carefully designed protocols and evidence that stands up to regulatory review. As this therapeutic area matures, operational excellence may become just as important as scientific innovation

Bottom line

Depression is becoming the next obesity-scale market, not because it’s trendy, but because unmet need, commercial proof and scientific progress have finally aligned. As with GLP-1 therapies, the winners won’t be the companies that announce the biggest deals. They’ll be the ones that successfully translate promising science into robust clinical evidence and ultimately into approved medicines.

As this therapeutic area continues to evolve, sponsors will need more than innovative molecules. They will need clinical development strategies capable of navigating regulatory complexity, operational challenges and global execution. That is where the next generation of market leaders will be defined.